ABT

Company overview

Abbott Laboratories is a diversified healthcare company operating across medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals, with a particularly strong position in continuous glucose monitoring devices.

Business model

Abbott earns revenue from a broad range of healthcare products sold to hospitals, clinics, and consumers globally, with its diversification across four distinct segments reducing dependence on any single product category.

Growth drivers

• Continuous glucose monitor adoption growth
• Diagnostics testing volume normalization
• Medical device pipeline expansion
• International nutrition product growth

Competitive position

Abbott's diversified portfolio and leading position in continuous glucose monitoring give it multiple avenues for growth, reducing the single product risk that affects more narrowly focused medical device companies.

Risks

Currency fluctuations affect its large international revenue base, diagnostics testing demand has normalized from pandemic era highs, and competition in glucose monitoring is intensifying as more entrants join the category.

Valuation

Abbott trades at a premium multiple typical of diversified healthcare companies, with the glucose monitoring business increasingly viewed as the primary growth driver supporting that premium.

Final view

Abbott's diversification across devices, diagnostics, and nutrition provides a balanced growth profile. My view is favorable given the strength of its glucose monitoring franchise, with competitive intensity in that category worth monitoring.

Overall rating: 76/100